What Researchers Did
Researchers investigated prognostic factors for hyperbaric oxygen therapy (HBOT) efficacy in 134 patients with hemorrhagic radiation cystitis treated in France.
What They Found
Hyperbaric oxygen therapy (HBOT) showed an efficacy of 83% at 3 months and 81% at 12 months for hemorrhagic radiation cystitis, with hospitalizations decreasing by 75%. Initial hematuria grade, high WHO status, and anticoagulant use negatively impacted HBOT efficacy, while 20% of patients experienced minor side effects.
What This Means for Canadian Patients
Canadian patients with hemorrhagic radiation cystitis might benefit from hyperbaric oxygen therapy, especially if treated early and without severe initial symptoms or anticoagulant use. Understanding these prognostic factors can help clinicians identify patients most likely to respond well to HBOT.
Canadian Relevance
This study has no direct Canadian connection as it was conducted in France.
Study Limitations
This study was conducted at a single center in France, which may limit the generalizability of its findings.